Rosenman D-Series: Ryan Pierce, Nine, Rock Health, & Stanford: "The First Dollar: Strategies and Ethics of Seed-Stage Fundraising"

What is the right way to raise a seed round?  Even as founders strive to focus on innovation and execution, they must make myriad decisions, big and small, on fundraising.  Whom should I pitch first?  What's the smallest check I should accept?  Do I price the round or raise on a convertible note, and on what terms?  Join us as healthcare product designer, entrepreneur, and investor Ryan Pierce tests conventional wisdom against a survey of his peers, considers the ethics of taking early-stage money, and shares his own lessons from both sides of the table.

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
5:00 to 6:30 PM, Tuesday, December 11

Agenda

5:00 - 5:30 pm: Networking
5:30 - 6:30 pm: Talk and Q&A

About the Speaker

pierce headshot.jpg

Ryan Pierce is Co-Founder and CEO of Nine, Entrepreneur-in-Residence at Rock Health, and Lecturer in Bioengineering at Stanford, where he teaches BIOE 70Q: Medical Device Innovation.  He has served as VP of Design and Innovation at Ventus Medical, VP of Business Development at Loma Vista Medical, a healthcare investor at De Novo Ventures, and a product designer at Concentric Medical and The Foundry/Zephyr Medical.  An inventor on over two dozen issued U.S. patents, he has designed FDA-cleared devices to treat sleep apnea and stroke.  Ryan holds mechanical engineering degrees from MIT and Stanford, and an MBA from Harvard Business School.

QB3 Seminar: Wendell Lim, UCSF. "Cell Design Labs from Launch to Acquisition"

Wendell Lim, a leader in synthetic biology, chairs the Department of Cellular and Molecular Pharmacology at UCSF. He co-founded Cell Design Labs in 2015 with Brian Atwood of Versant Ventures. Cell Design Labs, developing two technologies in the CAR-T cell cancer immunotherapy space, made such rapid progress that it was acquired two years later by Gilead for $567 million. Join us to hear about Wendell's experience launching Cell Design Labs and the lessons he learned commercializing a cutting-edge technology.

Where and When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Noon to 1:00 PM, Thursday, December 6

About the Speaker

Wendell_Lim_molecule.jpg

Wendell Lim is the Byers Distinguished Professor and Chair of the Department of Cellular and Molecular Pharmacology at the University of California San Francisco, and an Investigator of the Howard Hughes Medical Institute. He received his A.B. in Chemistry, summa cum laude, from Harvard College, his Ph.D. in Biochemistry and Biophysics at the Massachusetts Institute of Technology and completed his postdoctoral training at Yale University. His research focuses on the design principles of molecular circuits that govern cell decision-making and responses. His lab has made contributions in understanding the molecular machinery of cell signaling and how molecular modules have been used in evolution to build novel new behaviors. Most recently he has been a pioneer in the emerging field of synthetic biology, exploring how these design principles can be harnessed to engineer cells with customized therapeutic response programs. He is an author of the textbook, Cell Signaling (Garland Science 2014) and was the founder of the cell therapy biotech startup, Cell Design Labs, which was acquired by Gilead Biosciences in 2017.

Rosenman D-Series: Sanaz Saatchi, CrownPoint Medical: "Approaches to Innovation: From Strategics to Start-Ups"

How are areas of opportunity for medtech invention discovered? Is there a single optimal approach to healthcare innovation or are there multiple approaches that work equally well? Do global healthcare companies use the same framework for innovation as start-up companies? Join us on October 30th to hear Dr. Sanaz Saatchi’s perspective and recommended methodologies to drive innovation. Previously, Dr. Saatchi led the development of cardiovascular medical devices from inception to commercial launch at Medtronic and helped multiple start-up companies determine the strategic product-market fit for novel technologies.

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
5:00 to 6:30 PM, Tuesday, October 30

Agenda

5:00 - 5:30 pm: Networking
5:30 - 6:30 pm: Talk and Q&A

About the Speaker

Sanaz Bio Pic_2018.jpg

Sanaz has a unique combination of technical leadership and marketing expertise. While at Medtronic as an R&D Engineering Manager, she led a cross-company team to develop two cardiovascular medical devices through all phases of innovation - from inception to commercial launch. This includes needs finding, concept generation, device design, product development, high volume manufacturing, and global commercial launch. Medtronic's decision to invest in the coronary therapy delivery space with the development of these two new products stemmed directly from a global needs finding initiative led by Sanaz in partnership with IDEO. She played a critical role in conducting the research, synthesizing a strategy, and gathering organizational support to create multiple new product development programs.

Beyond her technical leadership capabilities, Sanaz also has a critical understanding of the medical device industry business needs, customer interface, and commercialization process. As a Product Marketing Manager at Medtronic, Sanaz helped drive the global launch of these two cardiovascular medical devices with a $250M market size. In addition to engineering, marketing, and leadership roles in public companies, including Medtronic and Becton Dickinson, Sanaz also has experience in technical and strategic consulting to start-ups, venture capital firms, and non-profit organizations.

Sanaz has expertise in the Stanford BioDesign Process to identify unmet healthcare needs and develop solutions. Sanaz holds a Ph.D. in Bioengineering from Stanford University, a M.S. in Mechanical Engineering from MIT, and a B.S. in Bioengineering from UC Berkeley. She is an inventor and published author on 10 patents and scientific publications, and an invited speaker at various conferences, including Cardiovascular Research Technologies and MedTech Vision highlighting female leaders within the medtech industry.

Rosenman D-Series: Rajan Patel, iO life science. "Learn About Experience Design for Medical Devices"

If your product addresses a viable market, it will have competition. Your commercial success can depend to a large extent on the good or bad experience that users--clinicians and patients--have while using your device or system. How can you ensure that users have a good experience? Join us to learn from Rajan Patel, founder and CEO of the firm iO life science. (Speaker info has been updated from the original)

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Thursday, November 29, 2018, 5:30 to 6:30 PM

Agenda

5:30 - 6:15 PM: Talk
6:15 - 6:30 PM: Q&A

About the Speaker

patel+lg 300.png

Rajan Patel is a medical device executive who partners with healthcare brands to transform their design & development practices. After 30+ years of medical device development across drug delivery, diagnostic systems, surgical devices and digital medicine, Rajan knows what truly drives innovation of smart, connected and patient-centric devices. It’s about collaborating with partners who are dedicated to creating breakthrough therapeutic solutions to unmet patient needs. Rajan has held senior positions across such companies as Minimed, Heartport, Aerogen, M2 Medical, Cirtec Medical and Lunar, leading programs to develop & commercialize medical products. Rajan’s commitment over the past 15+ years has been to organizations dedicated to transforming lives through revolutionary drug delivery and medical device technologies. Rajan has led numerous research & development and manufacturing teams to successful execution and launch of life-impacting devices. Rajan holds a B.S. in Mechanical Engineering from MS University of Baroda and M.S. in Biomedical Engineering from UC Davis/CSUS.

QB3 Seminar: Amy Trejo, P&G: "Partnering, Business Models, and Consumer Insight at P&G"

The consumer products company Procter & Gamble maintains a strong initiative in innovation, developing new products to meet consumer needs. Partnership, licensing, and acquisition are all active options. P&G actively seeks startups with technologies in areas of Life Science (including microbiome and aging), Chemistry, Materials Science, Smart Products (including AI) and Advanced Packaging. Join us to hear from Amy Trejo, Open Innovation Manager at P&G, about the company’s perspective and insights on innovation in consumer products. View the P&G one-page needs statement

Interested in meeting one-on-one with Dr. Trejo before her talk to discuss partnering with P&G? Apply for a timeslot

Where & When

Tuesday, November 27, 2018
Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)

About the Speaker

AVT-headshot1.jpg

Amy Trejo received her BSc. in Biology from Smith College in Northampton, MA and PhD in Cell and Molecular Biology from Northwestern University in Chicago, IL. She started with The Procter & Gamble Company in Cincinnati, OH in 1998 with responsibility for developing up-stream skin care technology for P&G’s Olay skin care brand. From there she moved on to manage upstream technology in the Health Care category working on digestive wellness brands with focus on the Align probiotic product. She then moved into product development managing new product innovation for Head & Shoulders. For the past 4 years Amy has worked as part of the Corporate Open Innovation Team, working to bring the best of external technologies into P&G to accelerate and strengthen their R&D programs.

Meet the FDA: Kyung Sung & Johnny Lam, FDA-CBER. "Regulatory science insights into cell-based products and practical microscale technologies for their assessment"

"Regulatory science insights into cell-based products and practical microscale technologies for their assessment"

Kyung Sung, Ph.D., Principal Investigator

Johnny Lam, Ph.D., Staff Fellow

Cellular and Tissue Therapies Branch, Division of Cellular and Gene Therapies, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research

This event is held in partnership with UCSF-Stanford CERSI.

As described in the 21st Century Cures Act, products eligible for Regenerative Medicine Advanced Therapy (RMAT) designation include cellular therapies, therapeutic tissue engineered products, human cell and tissue products, or any combination products that use such therapies or products. Multipotent stromal cells (MSCs) and induced Pluripotent Stem Cells (iPSCs) have been popular sources for manufacturing RMAT products due to their ability to undergo lineage-specific differentiation. Despite great promise, successful clinical translation of such cell-based products is often hindered by manufacturing challenges and the lack of reliable markers that can predict the products’ in vivo performance. For instance, MSCs are very heterogeneous and responsive to their surrounding environment, resulting in distinct subpopulations of cells with potentially different amounts of qualities needed for product potency. Since there are numerous biochemical and biomechanical factors regulating the functions of MSCs, it is critical to develop reliable high-throughput assays that enable the efficient exploration of large and complex parameter spaces for evaluating cellular function. Microscale in vitro systems offer the practicality to fulfill this unmet need. Several simple microfluidic channel arrays have been successfully implemented in screening the influence of paracrine mediators and various tissue microenvironment components in the regulation of cellular functions. In addition, microphysiological three-dimensional organoids and tissue-like structures such as chondrogenic cell aggregates and blood vessels have been incorporated into high-throughput, cell-based screening platforms in efforts to provide functionally relevant in vivo-like conditions. This presentation will give an overview of practical microscale technologies that are simple to operate while enhancing throughput, relevance, and reliability. How such technologies could be employed in the assessment of cell-based products will be discussed.

Where & When

Room 2103, Mission Hall, UCSF Mission Bay (550 16th St., San Francisco)
2:00-3:00 PM, Friday, November 9

About the Speakers

Johnny Lam 200px.jpg

Dr. Johnny Lam is a biomedical engineer with expertise in biomaterials and in developing practical microscale in vitro tools for medical and biological applications. Dr. Lam’s main research interests involve studying multipotent stromal cells (MSCs, otherwise known as mesenchymal stem cells) and how their quality attributes relate to their functional potential using physiologically relevant, higher-throughput platforms. Dr. Lam received his Ph.D. in Bioengineering in 2015 at Rice University, where he developed and evaluated injectable multi-layered hydrogel composites for cell and controlled growth factor delivery for in vivo cartilage tissue repair. Following his graduate studies, Dr. Lam joined the Center for Biologics Evaluation and Research at the FDA as a post-doctoral researcher, where he now works as a Staff Fellow. His research now focuses on the development and adaptation of wide-ranging microphysiological platforms to evaluate various functional outcomes of MSCs toward improving the quality and potency of manufactured cell-based products.

Kyung Sung 200px.jpg

Dr. Kyung Sung is a biomedical engineer with expertise in developing functional and practical microscale in vitro tools for medical and biological applications. Dr. Sung’s main research interests lie in studying cell-materials interactions and exploring cell behavior in various tissue microenvironmental conditions. Dr. Sung received her Ph.D. in Chemical Engineering in 2007 at the University of Michigan, and worked as a post-doctoral researcher in the Department of Biomedical Engineering at the University of Wisconsin-Madison, where she also worked as a Principal Investigator before she joined the FDA in 2015. She also worked as a patent examiner in Biotechnology at the US Patent and Trademark Office. During her previous research, she used principles from tissue and microsystems engineering to develop tissue-like structures such as blood vessels and mammary ducts in microfluidic channels to develop new practical tools to conduct cancer research in vitro. The microscale in vitro systems provide unique capabilities when studying complex interactions occurring in tissue microenvironment, by providing more precise controls of biochemical and biomechanical factors than traditional platforms. She has been able to create innovative opportunities and strategies for researchers to explore biology in different ways – particularly in understanding the role of the tissue microenvironment in regulating cellular functions.

QB3 Seminar: Lindred Greer, Stanford. "How to Build a Resilient, Winning Team"

A startup’s chances of success depend critically on the people who make up the founding team. Some conflict is inevitable, but different outlooks and temperaments among founders can ultimately make a company stronger or destroy it. What should you think about when looking for co-founders? Join us to learn from Lindred Greer, associate professor of organizational behavior at the Stanford Graduate School of Business. Professor Greer’s work focuses on the impact of team composition on intragroup conflict and team performance. She has a particular interest in how early-stage startup teams are composed in terms of power, status, and leadership structures, and when and why these structures may fuel power struggles and conflicts.

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Noon to 1:00 PM, Tuesday, November 6, 2018

About the Speaker

sgsb-0004_lindred_greer-rt-web.jpg

Lindred L. Greer is an Associate Professor of Organizational Behavior and she teaches the core Groups and Teams course in the MBA program. Professor Greer’s work focuses on the impact of team composition on intragroup conflict and team performance. She has a particular interest in how teams, particularly early stage start-up teams, are composed in terms of power, status, and leadership structures, and when and why particular forms of team composition may fuel power struggles and conflicts. When investigating teams, she often adopts a multi-level theoretical approach in understanding how individuals within the same team may differentially experience team structures and processes. In carrying our her research, she employs a variety of methods, including field (ranging from survey to quasi-experimental studies), laboratory, and archival research. Her research appears in academic journals such as the Academy of Management Journal, Journal of Applied Psychology, Organizational Behavior and Human Decision Processes, and Science.

Professor Greer is on the editorial boards at the Academy of Management Journal, Administrative Science Quarterly, Journal of Applied Psychology, Journal of Experimental Social Psychology, Journal of Personality and Social Psychology, and Organizational Behavior and Human Decision Processes, and served as Associate Editor of the journal Small Group Research (2011-2015).

Professor Greer joined the Stanford Graduate School of Business in 2013. She received her BS at the Wharton School of Business at the University of Pennsylvania and her PhD in Social and Organizational Psychology at Leiden University in the Netherlands.

Staying Younger Longer 2.0

As we age, our minds and bodies degenerate. Older people suffer pain, can't enjoy the activities they used to, forget things, and aren't as sharp mentally as younger people. But what if it were possible to slow this general decline and improve the quality of life for the aging? We would live in a happier and more productive society.

In recent years, QB3 has increasingly focused on aging-related disease. We've brought scientists together from Bay Area universities and the private sector. We want to spark productive collaborations that lead to understanding the process of aging and, ultimately, solutions to help all of us. This October, we've invited key players in the field to join us at an afternoon symposium at UCSF Mission Bay.

If you would like to learn about new research, meet leading scientists, connect to investors, and be a part of an exciting group that identifies and tackles one of the most important problems facing us today, please attend this symposium. Space is limited!

Slides

Susanna Rosi: Treatment Strategies to Prevent and Reverse Cognitive and Behavioral Deficits after Brain Injury

Agenda


1:00 - 1:15 PM Registration

1:15 - 1:20 PM Reg Kelly (QB3): Introduction

Session I: Recent developments in understanding aging suggest that anti-aging therapies are on the horizon.

1:20 - 1:50 PM Eric Verdin (Buck Institute): "Therapy and Diagnostic Development at the Buck Institute"

1:50 - 2:10 PM Tony Wyss-Coray (Stanford): "Aging Factors in the Blood"

2:10 - 2:30 PM Susanna Rosi (UCSF): "Stress-Induced Acceleration of the Aging Process"

2:30 - 3:00 PM Coffee Break

Session II: To bring theory into practice we need biomarkers to predict disease, quantify disease progression and stratify age-related diseases.

3:00 - 3:20 PM Ron Kohanski (National Institute on Aging): "Biomarker Research"

3:20 - 3:35 PM Ben Kamens (Spring Discovery): "Applying AI Techniques to Data Analysis of Aging Biomarkers"


3:35 - 3:50 PM Kimberly Scearce-Levie (Denali Therapeutics): "Neurofilament as a Clinical Biomarker of Progression and Response"


3:50 - 4:05 PM Eric Morgen (BIOAGE): "From Longevity Biomarkers to Drug Targets"

Session III: We need to decide on the next steps to be taken for aging biomarkers.

4:05 - 5:15 PM Panel discussion: Supporting biomarker development for aging-related diseases. Moderator: Joe Betts-LaCroix (Vium)

  • Laura Deming (Longevity Fund)

  • Chris Haskell (Bayer)

  • Ron Kohanski (NIA)

  • John Newman (UCSF & Buck)

  • James Peyer (Apollo Ventures)



5:15 - 5:30 PM Reg Kelly: Closing Remarks

5:30 - 7:00 PM Reception

QB3 Seminar: Atessa Chehrazi & Ilana Drummond, Jackson & Hertogs. "US Immigration Policy for Life Science Employees and Entrepreneurs"

More than half of the startups in the QB3 network were founded by entrepreneurs not born in the US. And many startups hire foreign scientists because of their specialized skills. But the procedures for applying for visas, which have never been simple, have become more complicated of late. To learn more about how executive orders, and recent bills introduced in Congress, may affect your company’s hiring or your own employment prospects—and to get a refresher on the US immigration system—join us to hear from Atessa Chehrazi and Ilana Drummond of the San Francisco immigration law firm Jackson & Hertogs.

Where and When

Room 212, Byers Hall, UCSF Mission Bay (700 4th St., San Francisco)
Noon to 1:00 PM, Tuesday, October 9

About the Speakers

Atessa023.JPG

Atessa Chehrazi has been a partner at Jackson & Hertogs since April 2013 and an associate/senior associate since July 2000. She was previously an associate at Maggio & Kattar in Washington, D.C. from 1996 to 2000. She has held several volunteer roles within the American Immigration Lawyers Association (AILA) during her career. For AILA’s Northern California Chapter, she has served as Chair, Vice-Chair, Treasurer, U.S. Citizenship & Immigration Service (USCIS) liaison. On a national level, Atessa served on AILA’s USCIS Headquarters and Benefits, Administrative Appeals Office (AAO), and Department of Labor (DOL) liaison committee. In addition, Atessa has served on AILA’s Business Immigration Advocacy, Issues, and Due Process & Civil Liberties committees, as well as several conference committees. She has served on both a chapter level and national level as a Customs & Border Protection (CBP) liaison.

Atessa has authored articles published in AILA Handbooks and has presented at national and regional AILA conferences. Atessa has served as a board member of the Iranian American Bar Association Northern California chapter since 2009, served as President of the chapter 2014-2015, and was the chapter honoree at the Bar Association of San Francisco Minority Bar Council annual unity awards event in 2014. She is a member of the National Lawyers Guild and was the NLG Immigration Project’s honoree in 2013.

Ilana0037.jpg

Ilana J. Drummond has been the firm’s managing partner since 2004. Having focused her practice exclusively on immigration matters for her entire career, Ilana has developed an expertise in helping large and small corporations address their immigration needs. Ilana has held a number of roles within the AILA organizations over the years, including roles within AILA’s California Service Center Liaison Committee, Distance Learning Committee, L-1 Visa Taskforce, and the USCIS Benefits Liaison Committee. Ilana has been an invited speaker to several national and regional conferences. She recently authored “Hiring International Workers in Today’s Economy: New Challenges and Strategies” to Aspatore’s 2010 edition of Employing International Workers. Ilana has received accolades from several directories to legal counsel, including Martindale-Hubbell® and Chambers USA.

Info session for NSF I-Corps short course

Find out about how participating in a three-evening NSF program known as "I-Corps" can significantly de-risk your startup venture. The program trains attendees to use customer discovery and the Lean LaunchPad method to test your product-market fit. Come to this information to get all your questions answered. This is also an opportunity to find like-minded people who are looking to build a team or join one. See you there!

The course will be held evenings of 10/15 (Mon), 10/17 (Wed), and 10/22 (Mon). Short applications are due October 10. Apply HERE if you already know you want to join the program.

Where and When

Monday, October 8, 4:30 to 6:00 PM
Room 215, Byers Hall, UCSF Mission Bay (1700 4th St.)

Questions? Email gino.segre@ucsf.edu

Fall SBIR Grantwriting Workshop at Berkeley

"How to Write a Winning SBIR Proposal"

When & Where

Location is 177 Stanley Hall, UC Berkeley
All classes are on Wednesdays. Class dates: Oct. 3, Oct. 17, Oct. 24, Nov. 14
Scroll down to buy tickets.

About the Workshop

The chances of your SBIR or STTR proposal getting funded are vastly improved if your proposal is well written and packaged. In fact, many great ideas fail to get funded simply because of poor “grantsmanship.” In addition, first-time applicants are often daunted by the intricacies of the grant submission and review processes, and are unaware that they can improve their chances of getting funded by communicating directly with funding agency program and review staff.

This workshop will help you develop a compelling, well-organized research plan, and explain your ideas in clear, engaging writing that will win over your reviewers. We will focus on the Research Plan sections of NIH and NSF SBIR proposals, and one full session will be devoted to helping you craft your Specific Aims (the most important section of your application). We will also provide guidance on filling out your budget, Biosketch and other forms, and tips on how to most effectively navigate the NIH and NSF application and review processes.

Specific topics to be covered will include:

  • What are SBIRs and STTRs, and which should you apply for?

  • Finding a “home” for your proposal (funding agencies, study sections, and topic-specific funding opportunities)

  • Sussing out your competition

  • Interacting with funding agency staff

  • Developing a logical, fundable Research Plan and assembling your project team

  • Logistics of the application process (electronic submission, deadlines, timelines to funding, agency requirements)

  • Major components of SBIR/STTR Research Plans and what to include in each

  • Facing and conquering the blank page

  • Writing and packaging your proposal for maximum impact

  • How to avoid common mistakes

  • Individualized feedback on your Specific Aims

  • Developing your Budget

  • Filling out forms

  • Review and award processes

  • The workshop will consist of four 3-hour sessions. There will be time during and at the end of each session for class participants to consult with the instructors about their own applications.

Session 1: Introduction to SBIRs and STTRs; identifying appropriate funding agencies and targeted funding announcements; mechanics of applying

Session 2: Developing your Research Plan; grantsmanship and writing tips (i.e., how to best pitch your proposal to your reviewers)

Session 3: Individual feedback from the instructors on your Specific Aims; help with filling out forms

Session 4: The review and award processes and how to maximize your chances of success; resubmissions and Phase II applications

This class is designed for applicants planning to submit for the next NIH and/or NSF grant deadlines (Jan 5, 2019 and early December 2018, respectively). However, the basic principles to be covered also apply to other federal SBIR funding agencies (DoD, DoE, etc.). Importantly, the science writing skills taught in this class will serve you well in writing not only grant applications, but also scientific journal articles and company public relations materials.

Register Now

Please note that if you wish to request a refund we require notice of cancellation 48 hours in advance of the first session.
 

Fee Structure

General Admission: $750
Startup in a Box members: $150

Note: Startup in a Box fee for UC founder: $250, non-UC founder: $350. More information on the program is available here.

Email Ioana Aanei with any questions.

About the Instructor

gabrielle.png

Gabrielle G. Leblanc, Ph.D., is a professional grant consultant and writer with 11 years of experience as an NIH Program Director, and many years of prior experience as a research scientist and lab PI. During her academic career, she was an Assistant Professor at Oregon Health Sciences University, where her laboratory studied early nervous system development. As a lab PI, Dr. Leblanc was successful in winning grants from NIH, NSF, and many other government and non-profit funding agencies. As a Program Director at the National Institute of Neurological Disorders and Stroke at NIH, she oversaw multimillion dollar portfolios of grants and contracts in basic and clinical science, provided grantsmanship advice to scores of both junior and senior investigators, and led major funding initiatives in neuroscience, developmental biology, and genomics. In her subsequent 10 years as a freelance grant consultant/writer, she has provided scientific strategic consulting and grant-writing support to biotechnology industry and university investigators in a wide range of fields, from trypanosome pharmacogenomics to cancer drug development to medical applications of virtual reality. Dr. Leblanc has a B.A. in Biology from Harvard University and a Ph.D. in Neurosciences from Stanford University School of Medicine.

Office Hours: Fundraising. Aria Kashefi, Morrison Foerster

Our office hours are hosted by leading experts who have generously offered their services pro bono to our entrepreneurs.

To hold your slot for this session, we require a $100 credit card deposit. The deposit will be refunded the day after you attend. No-shows will not receive a refund. Please be punctual; arrivals late by more than 15 minutes will be considered no-shows.

If you find that you are unable to attend, you may request a refund up to 48 hours in advance. We regret that we cannot honor requests made at a later time.

Where & When

Suite 214, Byers Hall, UCSF Mission Bay (1700 4th Street, San Francisco)
9:00AM to 12:00PM, Wednesday, October 3

Reserve Your Slot

About the Expert

aria_kashefi.jpg

Aria Kashefi is an associate in the Palo Alto office of Morrison & Foerster and is a member of the firm’s Corporate Group.

Mr. Kashefi’s practice focuses on emerging company and venture capital financings, mergers and acquisitions of technology companies and other corporate, securities and commercial matters.

Mr. Kashefi earned his B.A.Sc. (with distinction) in mechatronics, robotics and automation from the University of British Columbia in 2008 and received his J.D. from the University of Toronto in 2011, where he served as an Executive Member of the Business Law Students Association. Prior to joining Morrison & Foerster, Mr. Kashefi was an associate at an international law firm headquartered in Canada.

Mr. Kashefi is admitted to practice in California and in Ontario, Canada.

Office Hours: Licensing. Scott Carter, Morrison Foerster

Our office hours are hosted by leading experts who have generously offered their services pro bono to our entrepreneurs.

To hold your slot for this session, we require a $100 credit card deposit. The deposit will be refunded the day after you attend. No-shows will not receive a refund. Please be punctual; arrivals late by more than 15 minutes will be considered no-shows.

If you find that you are unable to attend, you may request a refund up to 48 hours in advance. We regret that we cannot honor requests made at a later time.

Where & When

Suite 214, Byers Hall, UCSF Mission Bay (1700 4th Street, San Francisco)
1:00 PM to 4:45PM, Wednesday, September 26

Reserve Your Slot

About the Expert

ScottCarterheadshot.jpg

Scott Carter focuses his practice on the life sciences industry, representing life sciences companies and investors in complex transactions relating to the development and commercialization of biotechnology, pharmaceutical, diagnostic, and medical-device products. He has extensive experience negotiating corporate partnership, licensing, research and development, clinical trial, manufacturing, and supply agreements. Dr. Carter also advises clients on the intellectual property aspects of mergers and acquisitions.

Dr. Carter holds a Ph.D. in chemistry from the California Institute of Technology. His research at Caltech centered on non-natural nucleosides, as well as the design, synthesis, and testing of DNA-binding molecules in the laboratory of Peter Dervan.

While at Caltech and law school, Dr. Carter was also the assistant director of the Office of Technology Transfer at Caltech. In this role, he managed the Institute’s life sciences patent portfolio, and negotiated and drafted license, research, and material transfer agreements, as well as advising Caltech entrepreneurs on new ventures.

Dr. Carter is admitted to practice in California and before the U.S. Patent and Trademark Office.

Fall SBIR Grantwriting Workshop at UCSF

Where & When

Room 1400, Mission Hall, UCSF Mission Bay
All classes are on Tuesdays, 1:00-4:00 pm
Class dates: Sept. 25, Oct. 16, Oct. 23, Nov. 6, Nov. 27, Dec. 18
Scroll down to buy tickets.

About the Workshop

This workshop will take you through all the steps necessary to successfully file a well-written NIH SBIR/STTR grant application for the January 5, 2019 deadline. Taking the workshop you will learn how to craft an appropriate research plan, obtain persuasive letters of support, develop an efficient budget, and anticipate reviewers’ comments. We will help you speed through the application instructions, saving you hours of time. Results from past attendees indicate that taking this course triples your chances of success. The workshop culminates in a submission clinic that will ensure your application is correctly filed.

One or more team members (up to 3) from the company should be prepared to attend every session. Remember to bring your laptop; these will be working sessions.

The course includes six working sessions and a pre-submission review of your Specific Aims page by our course instructors.

(The Oct. 23 class is guest talk & interactive workshop on Specific Aims page)

Topics

  • Understanding the eligibility requirements of an SBIR grant

  • Preparing to apply for an SBIR (company formation, registration at all required websites, identifying the best PI)

  • Assembling all the necessary parts of the application (letters of support, sub-contract quotes and letters, facilities description, research plan, etc.)

  • Strategies for designing your specific aims

  • Budget strategies and restrictions

  • Complete and convincing budget justifications

  • Documentation required to use human samples, human subjects and vertebrate animals

  • What makes a competitive proposal

  • Common mistakes that applicants make

  • Filing in forms and submission process

  • Re-submission if your grant is not funded

  • Phase II SBIR applications

  • Searching for program announcements and finding non-dilutive funding opportunities

Instructors

Shauna Farr-Jones, PhD, UCSF/QB3 grant writer
Ioana Aanei, PhD, Entrepreneurship Program Manager, QB3
Kaspar Mossman, PhD, Director of Marketing & Communications, QB3

Register Now

Please note that if you wish to request a refund we require notice of cancellation 48 hours in advance of the first session.

Fee Structure

General Admission: $750
Startup in a Box members: $150

Note: Startup in a Box fee for UC founder: $250, non-UC founder: $350. More information on the program is available here.

Email Ioana Aanei with any questions.

About the Instructor

SFJ Bixby.jpg

Shauna Farr-Jones, Ph.D., has a record of writing successful government grant and contract proposals on diverse life science topics, providing strategic input on both research and business plans. She has helped companies secure over $200 million in grant and contract funding from numerous government and philanthropic organizations, including BARDA, NIH, DTRA, USDA, DARPA and the Bill and Melinda Gates Foundation. For 17 years, she has consulted for life science companies and universities, identifying funding opportunities, preparing research plans, marketing plans, technical reports INDs, NDAs, white papers and proposals. She is also the Project Manager of the Antibody Technology Research Center at UCSF. Previously, she was Senior Writer at BioCentury Publications, where she analyzed and wrote about the biotechnology industry. She was a post-doctoral fellow at UCSF and has a Ph.D. in Biochemistry from Tufts University.

QB3 Seminar: Nick Shenkin, FBI. "IP Piracy in Life Science: Threat Landscape and Defensive Tactics"

For many life science startups, IP is the most crucial factor that determines whether they succeed or fail. An innovative concept and freedom to operate are essential to winning investment.

But hostile foreign and domestic actors want to steal ideas and data from scientists and entrepreneurs. They target the most vulnerable: academics and early-stage companies.

Are you one of these targets? Do you want to know what threats you face and what you can do to protect yourself? Join us on Thursday, September 13 to hear from FBI Special Agent Nicholas Shenkin, Strategic Partnership Coordinator for the FBI’s San Francisco Field Office.

This event is co-hosted with UCSF IT Security.

Where and When

Byers Auditorium, Genentech Hall, UCSF Mission Bay (600 16th St., San Francisco)
Noon to 1:00 PM, Thursday, September 13, 2018

About the Speaker

shenkin.jpg

Nicholas Shenkin is an FBI Special Agent and Director of the Strategic Technology Taskforce of the FBI, San Francisco Field Division. Nicholas is a Counterintelligence specialist and leads a staff of Special Agents and Intelligence Analysts responsible for hardening the target of 400+ Cleared Defense Contractors, Silicon Valley, U.C. Berkeley, Stanford, Lawrence Livermore National Lab, Lawrence Berkeley National Lab, and all businesses and academic institutions in the San Francisco division. In 1996, prior to his engagement with the Bureau, Nicholas started a web hosting and online security consultancy. Nicholas sold that company in 2002 and became Director and in-house counsel focused on M&A matters and on security compliance issues surrounding HIPAA and SOX. Nicholas is a graduate of UCLA and Loyola Law School, Los Angeles, and is a member of the California Bar.

 

Rosenman D-Series: Russ Branaghan, Research Collective. "Demystifying the FDA’s Human Factors Guidance"

As part of FDA approval, a new medical device must follow guidelines for “Human Factors,” which address design and encompass usability and ergonomics. Because medical devices are so diverse, manufacturers often struggle to understand how the guidelines apply to their own product. At this talk, Dr. Russell Branaghan, Founder/President at Research Collective will describe strategies to help companies (1) improve their time to market and overall design through early implementation of human factors, and (2) pass their human factors validation test for FDA clearance.

Where & When

Room 212, Byers Hall, UCSF Mission Bay (1700 4th St., San Francisco)
Tuesday, September 11, 2018

Agenda

5:00 - 5:30 pm: Networking

5:30 - 6:30 pm: Talk and Q&A

About the Speaker

Russ Branaghan.jpg

Dr. Russell J. Branaghan serves as Founder/President at Research Collective, a Human Factors research firm, specializing in medical devices and healthcare technologies. Russ also serves as Associate Professor of Human Systems Engineering at Arizona State University and is a Visiting Professor of Human Factors in the Master of Product Design and Development Program at Northwestern. Before forming Research Collective, Russ spent 15 years in industry as Sr. Human Factors Engineer at Hewlett-Packard, an Advisory Human Factors Engineer at IBM and held leadership positions at Fitch, Big Red Rooster and Lextant.

QB3 NIH SBIR 2-part workshop for Sept. 5 deadline

Get expert help with your SBIR application from professional grant writer Shauna Farr-Jones so you can submit with confidence for the September 5th NIH SBIR deadline. Join our upcoming short-form workshop: two highly interactive sessions addressing any questions you have regarding content, forms, budget and logistics.

Session 1: 1:00 - 2:30 PM, Tuesday, August 7
Session 2: 1:00 - 2:30 PM, Tuesday, August 21

Both sessions will be held in Room 2110, Mission Hall, 550 16th St., UCSF Mission Bay.

Session 1 will focus on the research plan, budget and justification, bios, facilities, letters, human subjects and vertebrate animals.

Session 2 will cover how to re-submit a rejected application and dealing with forms and submission.

Bring your draft application and email questions to Shauna in advance. The workshop is intended for founders who have already registered their companies at SAM.gov.

About the Instructor

SFJ Bixby.jpg

Shauna Farr-Jones, Ph.D., has a record of writing successful government grant and contract proposals on diverse life science topics, providing strategic input on both research and business plans. She has helped companies secure over $200 million in grant and contract funding from numerous government and philanthropic organizations, including BARDA, NIH, DTRA, USDA, DARPA and the Bill and Melinda Gates Foundation. For 17 years, she has consulted for life science companies and universities, identifying funding opportunities, preparing research plans, marketing plans, technical reports INDs, NDAs, white papers and proposals. She is also the Project Manager of the Antibody Technology Research Center at UCSF. Previously, she was Senior Writer at BioCentury Publications, where she analyzed and wrote about the biotechnology industry. She was a post-doctoral fellow at UCSF and has a Ph.D. in Biochemistry from Tufts University.